iRHOM2 is a critical pathogenic mediator of inflammatory arthritis
YouTube.com/jclininvest—January 25, 2013
Jane Salmon, Carl Blobel, Priya Darshinee Issuree, and Thorsten Maretzky of Hospital for Special Surgery discuss the role of iRHOM2 in inflammatory arthritis.
- TNF-α has been implicated in the pathology of rheumatoid arthritis (RA) and other inflammatory diseases. RA patients are currently treated with TNF inhibitors, but these therapeutics have many deleterious side effects.
- iRHOM2 regulates the maturation of TACE, and enzyme that cleaves and releases TNF-α from the surface of myeloid cells that mediate inflammation during arthritis.
- Inactivation of the gene that encodes iRHOM2 (Rhbdf2) protects mice from inflammatory arthritis.
- These findings suggest that iRHOM2 could be a suitable therapeutic target for the treatment of RA.
View the video at YouTube.com/jclininvest.
Read the news release describing the study that was published Feb. 1 in the Journal of Clinical Investigation.